Functional inhibition of NF-κB signal transduction in αvβ3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IκB gene

Arthritis Research and Therapy

Volumn 8, Issue 1, 2006, Pages

  Ogawara, Ken Ichi ^a   Kułdo, Joanna M ^b   Oosterhuis, Koen ^c   Kroesen, Bart Jan ^b   Rots, Marianne G ^c   Trautwein, Christian ^d   Kimura, Toshikiro ^a   Haisma, Hidde J ^a   Molema, Grietje ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYL-GLYCYL-ASPARTIC ACID; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROGOL DERIVATIVE; OLIGOPEPTIDE; VITRONECTIN RECEPTOR;

ADENOVIRIDAE; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DOMINANT GENE; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; MUTATION; SIGNAL TRANSDUCTION; TRANSGENE;

ADENOVIRIDAE; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, DOMINANT; HUMANS; I-KAPPA B PROTEINS; INTEGRIN ALPHAVBETA3; MUTATION; NF-KAPPA B; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; SIGNAL TRANSDUCTION; TRANSGENES;

EID: 70350501443     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1885     Document Type: Article

References (40)

1. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
2. Paleolog EM: Angiogenesis in rheumatoid arthritis. Arthritis Res 2002, 4:S81-S90.
3. Ebnet K, Vestweber D: Molecular mechanisms that control leukocyte extravasation: The selectins and the chemokines. Histochem Cell Biol 1999, 112:1-23.
4. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD: The codependence of angiogenesis and chronic inflammation. FASEB J 1997, 11:457-465.
5. Baeuerle P: Pro-inflamLatory signaling: last pieces in the NF- κB puzzle? Curr Biol 1998, 8:R19-R22.
6. de Martin R, Schmid JA, Hofer-Warbinek R: The NF-κB/Rel family of transcription factors in oncogenic transformation and apoptosis. Mutat Res 1999, 437:231-243.
7. Hatada EN, Krappmann D, Scheidereit C: NF-κB and the innate immune response. Curr Opin Immunol 2000, 12:52-58.
8. Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM: Selective targeting of the nuclear factor-κB pathway enhances tumor necrosis factor-related apoptosis-inducing ligandmediated pancreatic cancer cell death. Surgery 2002, 132:127-134.
9. Thiele K, Bierhaus A, Autschbach F, Hofmann M, Stremmel W, Thiele H, Ziegler R, Nawroth PP: Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut 1999, 45:693-704.
10. Blackwell NM, Sembi P, Newson JS, Lawrence T, Gilroy DW, Kabouridis PS: Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable IkappaBalpha repressor. Arthritis Rheum 2004, 50 2675-2684.
11. Morel JC, Park CC, Woods JM, Koch AE: A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 2001, 276:37069-37075.
12. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C, Baeuerle PA: Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996, 39:583-591.
13. Viemann D, Goebeler M, Schmid S, Klimmek K, Sorg C, Ludwig S, Roth J: Transcriptional profiling of IKK2/NF-kappa B- and p38 MAP kinase-dependent gene expression in TNF-alpha-stimulated primary human endothelial cells. Blood 2004, 103(9):3365-3373.
14. Iimuro Y, Nishiura T, Hellerbrand C, Behrns KE, Schoonhoven R, Grisham JW, Brender DA: NFκB prevents apoptosis and liver dysfunction during liver regeneration. J Clin Invest 1998, 101:802-811.
15. Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, Meijer DK, Haisma HJ, Molema G: A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 2004, 15 433-443.
16. Kok RJ, Schraa AS, Bos EJ, Moorlag HE, Asgeirsdottir SA, Everts M, Meijer DK, Molema G: Preparation and functional evaluation of RGD-modified proteins as avβ3 integrin directed therapeutics. Bioconjug Chem 2002, 13(1):128-135.
17. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT: Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996, 70:6839-6846.
18. Denk A, Goebeler M, Schmid S, Berberich I, Ritz O, Lindemann D, Ludwig S, Wirth T: Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem 2001, 276 28451-28458.
19. Murakami S, Morioka T, Nakagawa Y, Suzuki Y, Arakawa M, Oite T: Expression of adhesion molecules by cultured human glomerular endothelial cells in response to cytokines: Comparison to human umbilical vein and dermal microvascular endothelial cells. Microvasc Res 2001, 62:383-391.
20. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM: Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 2004, 172:4535-4544.
21. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY: Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001, 276:7614-7620.
22. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, Giancotti FG: Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002, 22 5912-5922.
23. Oitzinger W, Hofer-Warbinec R, Schmid JA, Koshelnick Y, Binder BR, de Martin R: Adenovirus-mediated expression of a mutant IkappaB kinase 2 inhibits the response of endothelial cells to inflammatory stimuli. Blood 2001, 97:1611-1617.
24. Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H: Suppression of retinal neovascularization by the NF-kappa B inhibitor pyrrolidine dithiocarbamate in mice. Invest Ophthalmol Vis Sci 1999, 40 1624-1629.
25. Makarov SS: NF-kappaB as a therapeutic target in chronic inflammation: Recent advances. Mol Med Today 2000, 6 441-448.
26. Li A, Dubey S, Verney ML, Dave BJ, Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
27. Kale S, Hanai J, Chan B, Karihaloo A, Grotendorst G, Cantley L, Sukhatme VP: Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression. FASEB J 2005, 19 270-271.
28. Stupack DG, Storgard CM, Cheresh DA: A role for angiogenesis in rheumatoid arthritis. Braz J Med Biol Res 1999, 32 573-581.
29. Koch AE, Burrows JC, Haines GK, Carlos TM, Harlen JM, Leibovish SJ: Immunolocalization of endothelial and leukocyte adhesion molecules in human eheumatoid and osteoarthritic synovial tissues. Lab Invest 1991, 64:313-320.
30. Kriegsmann J, Keyszer GM, Geiler T, Lagoo AS, Lagoo-Deenadayalan S, Gay RE, Gay S: Expression of E-selectin messenger RNA and protein in rheumatoid arthritis. Arthritis Rheum 1995, 38:750-754.
31. Everts M, Asgeirsdottir SA, Kok RJ, Twisk J, de Vries B, Lubberts E, Bos EJ, Werner N, Meijer DK, Molema G: Comparison of Eselectin expression at mRNA and protein levels in murine models of inflammation. Inflamm Res 2003, 52:512-518.
32. Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij LF, Molema G: Targeting of RGD-modified proteins to tumAr vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 2002, 102:469-475.
33. Bakker AC, Van de Loo FAJ, Joosten LAB, Bennink MB, Arntz OJ, Dmitriev IP, Kashentsera EA, Curiel DT, van den Berg WB: A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Ther 2001, 8:1785-1793.
34. Perlman H, Liu H, Georganas C, Woods JM, Amin MA, Koch AE, Wickham T, Kovesdi I, Mano T, Walsh K, Pope RM: Modifications in adenoviral coat fiber proteins and transcriptional regulatory sequences enhance transgene expression. J Rheumatol 2002, 29:1593-1600.
35. Liu SF, Ye X, Malik AB: Pyrolidine dithiocarbamate prevents IkB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol 1999, 55 658-667.
36. Zhang HG, Huang N, Liu D, Bilbao L, Zhang X, Yang P, Zhou T, Curiel DT, Mountz JD: Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts. Arthritis Rheum 2000, 43:1094-1105.
37. Lee L, Buckley C, Blades MC, Panayi G, George AJ, Pitzalis C: Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum 2002, 46 2109-2120.
38. Garcia-Trapero J, Carceller F, Dujovny M, Cuevas P: Perivascular delivery of neomycin inhibits the activation of NF-kappaB and MAPK pathways, and prevents neointimal hyperplasia and stenosis after arterial injury. Neurol Res 2004, 26:816-824.
39. Smolen JS, Steiner G: Therapeutic strategies for rheumatoid arthritis Nat Rev Drug Discov 2003, 2:473-488.
40. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M: The two faces of IKK and NF-kappaB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003, 9:575-581.